TABLE 3.
DDKT recipient clinical data
| Age | Male | PRA | BMI | HLA mismatches | DGF risk | |
|---|---|---|---|---|---|---|
| IGF | 66 | N | 93% | 35.0 | 5/6 | 40% |
| 36 | N | 94% | 27.0 | 6/6 | 29% | |
| 66 | Y | 0% | 23.9 | 5/6 | 39% | |
| 25 | N | 90% | 20.6 | 4/6 | 34% | |
| 64 | N | 59% | 32.8 | 5/6 | 53% | |
| 51.4 (19.5) | 1/5 | 67.2 (40.3)% | 27.9 (6.0) | 5/6 | 39.0 (9.0)% | |
| DGF | 41 | Y | 0% | 35.0 | 5/6 | 26% |
| 26 | Y | 0% | 29.1 | 5/6 | 40% | |
| 47 | Y | 0% | 18.0 | 5/6 | 52% | |
| 70 | Y | 0% | 23.3 | 6/6 | 61% | |
| 59 | Y | 0% | 21.5 | 6/6 | 53% | |
| 45 | Y | 0% | 32.4 | 6/6 | 27% | |
| 48.0 (15.2) | 6/6 | 0 (0)% | 26.6 (6.7) | 5.5/6 | 43.2 (14.6)% | |
| P | 0.76 | 0.02 | 0.003 | 0.74 | 0.38 | 0.58 |
Summary data shown as mean (SD) where applicable, with P comparing IGF and DGF groups shown for each variable.
BMI, body mass index; DDKT, deceased donor kidney transplant; DGF, delayed graft function; IGF, immediate graft function; PRA, panel reactive antibody.